Last A$72.37 AUD
Change Today -0.23 / -0.32%
Volume 2.0M
CSL On Other Exchanges
Symbol
Exchange
OTC US
Munich
OTC US
As of 2:10 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSL) Snapshot

Open
A$72.65
Previous Close
A$72.60
Day High
A$72.77
Day Low
A$72.14
52 Week High
09/3/14 - A$75.13
52 Week Low
08/8/14 - A$63.77
Market Cap
34.4B
Average Volume 10 Days
1.1M
EPS TTM
A$2.70
Shares Outstanding
475.8M
EX-Date
09/8/14
P/E TM
24.3x
Dividend
A$1.24
Dividend Yield
1.71%
Current Stock Chart for CSL LTD (CSL)

Related News

No related news articles were found.

csl ltd (CSL) Related Businessweek News

No Related Businessweek News Found

csl ltd (CSL) Details

CSL Limited is engaged in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including vaccines to protect against viral and bacterial diseases; pharmaceuticals to treat a range of human medical conditions; diagnostic products to determine compatibility of donor-recipient blood in transfusion settings; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment is engaged in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

12,196 Employees
Last Reported Date: 08/12/14
Founded in 1916

csl ltd (CSL) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $3.1M
Chief Financial Officer
Total Annual Compensation: $1.6M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Manufacturing Ope...
Total Annual Compensation: $1.1M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $998.2K
Compensation as of Fiscal Year 2014.

csl ltd (CSL) Key Developments

CSL Ltd. Announces Audited Parent Earnings Results for the Year Ended June 30, 2014

CSL Ltd. announced audited parent earnings results for the year ended June 30, 2014. For the year, the company reported profit of AUD 1,055.4 million against AUD 1,398.8 million a year ago.

CSL Limited Announces Final Dividend Payable on 03 October 2014

CSL Limited announced a final dividend of $0.6485 per security. This is dividend is payable on 03 October 2014, ex-distribution/entitlement date is on 08 September 2014 and record date is on 10 September 2014.

CSL Ltd. Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2014; Provides Earnings Guidance for the Financial Year 2015

CSL Ltd. announced audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported total segment revenue of USD 5,501.9 million against USD 5,099.1 million a year ago. Consolidated revenue was USD 5,524.3 million against USD 5,129.5 million a year ago. Sales revenue from continuing operations was USD 5,334.8 million against USD 4,950.4 million a year ago. Profit before income tax expense from continuing operations was USD 1,604.3 million against USD 1,461.3 million a year ago. Net profit for the period from continuing operations was USD 1,307.0 million or USD 2.691 per diluted share against USD 1,211.4 million or USD 2.421 per diluted share a year ago. Consolidated EBIT was USD 1,637.2 million against USD 1,479.6 million a year ago. Consolidated EBITDA was USD 1,832.1 million against USD 1,681.2 million a year ago. Total capital expenditure was USD 401.9 million against USD 450.1 million a year ago. Net cash inflow from operating activities was USD 1,360.7 million against USD 1,311.7 million a year ago. Payments for property, plant and equipment was USD 353.9 million against USD 433.2 million a year ago. Payments for intangible assets were USD 48.0 million against USD 16.9 million a year ago. Net debt as at June 30, 2014 was USD 1,282 million against USD 917 million as at June 30, 2013. The main reason that the EBIT grew more strongly than NPAT in financial year 2014 was due to a step-up in the reported effective tax rate, from 17.1% to 18.5%. The company provided earnings guidance for the financial year 2015. The company announced that it continues to see robust global demand for plasma therapies. This financial year, at constant currency, the company expects net profit after tax to grow approximately 12% and earnings before interest and tax to grow approximately 15%. Earnings per share growth will again exceed profit growth expectations as shareholders benefit from the ongoing effect of past and current share buybacks. Similarly, current thinking in expectation of ongoing clinical success with CSL112, or rHDL, is to make the strategic manufacturing decision for that asset in financial year 2015 and to follow that decision with migrating the asset to the appropriate location. This will also net out in the consolidated accounts, but again, they will tend to inflate the effective tax rate during that year of migration. That's the main reason the company's EBIT growth guidance is stronger than NPAT growth guidance for financial year 2015. In light of these one-offs, EBIT is probably more indicative of underlying profit growth and the company's operational performance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSL:AU A$72.37 AUD -0.23

CSL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,584 JPY -6.50
Biocon Ltd 487.30 INR +7.85
Emergent Biosolutions Inc $22.33 USD +0.31
Grifols SA €32.78 EUR +0.31
Shire PLC 5,270 GBp -15.00
View Industry Companies
 

Industry Analysis

CSL

Industry Average

Valuation CSL Industry Range
Price/Earnings 24.4x
Price/Sales 5.9x
Price/Book 9.8x
Price/Cash Flow 23.8x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit www.csl.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.